Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tami L Bair

Showing results (111-120 of 133) with videos related to

Pageof 14
Sort By:
JAMA|November 18, 2014
Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trialJoseph B Muhlestein, Donald L Lappé, Joao A C Lima, et al.
JACC. Cardiovascular Imaging|December 19, 2021
Coronary Artery Calcium Versus Pooled Cohort Equations Score for Primary Prevention Guidance: Randomized Feasibility TrialJoseph B Muhlestein, Kirk U Knowlton, Viet T Le, et al.
American Heart Journal|April 21, 2009
Superior predictive ability for death of a basic metabolic profile risk scoreHeidi T May, Benjamin D Horne, Brianna S Ronnow, et al.
The American Journal of Medicine|June 3, 2009
Exceptional mortality prediction by risk scores from common laboratory testsBenjamin D Horne, Heidi T May, Joseph B Muhlestein, et al.
The American Journal of Cardiology|May 10, 2017
The Population-Based Long-Term Impact of Anticoagulant and Antiplatelet Therapies in Low-Risk Patients With Atrial FibrillationAnjani Golive, Heidi T May, Tami L Bair, et al.
Journal of Cardiovascular Electrophysiology|August 14, 2015
Percent Time With a Supratherapeutic INR in Atrial Fibrillation Patients Also Using an Antiplatelet Agent Is Associated With Long-Term Risk of DementiaVictoria Jacobs, Scott C Woller, Scott M Stevens, et al.
American Heart Journal|June 5, 2017
Atrial fibrillation incrementally increases dementia risk across all CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>VASc strata in patients receiving long-term warfarinKevin G Graves, Heidi T May, Victoria Jacobs, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|August 9, 2011
Red cell distribution width, C-reactive protein, the complete blood count, and mortality in patients with coronary disease and a normal comparison populationJason M Lappé, Benjamin D Horne, Svati H Shah, et al.
Journal of Cardiovascular Electrophysiology|May 29, 2009
Warfarin is not needed in low-risk patients following atrial fibrillation ablation proceduresT Jared Bunch, Brian G Crandall, J Peter Weiss, et al.
Pacing and Clinical Electrophysiology : PACE|September 8, 2011
Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocksT Jared Bunch, Srijoy Mahapatra, David Murdock, et al.
Pageof 14

Showing results (111-120 of 133) with videos related to

Sort By:
Pageof 14
JAMA|November 18, 2014
Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trialJoseph B Muhlestein, Donald L Lappé, Joao A C Lima, et al.
JACC. Cardiovascular Imaging|December 19, 2021
Coronary Artery Calcium Versus Pooled Cohort Equations Score for Primary Prevention Guidance: Randomized Feasibility TrialJoseph B Muhlestein, Kirk U Knowlton, Viet T Le, et al.
American Heart Journal|April 21, 2009
Superior predictive ability for death of a basic metabolic profile risk scoreHeidi T May, Benjamin D Horne, Brianna S Ronnow, et al.
The American Journal of Medicine|June 3, 2009
Exceptional mortality prediction by risk scores from common laboratory testsBenjamin D Horne, Heidi T May, Joseph B Muhlestein, et al.
The American Journal of Cardiology|May 10, 2017
The Population-Based Long-Term Impact of Anticoagulant and Antiplatelet Therapies in Low-Risk Patients With Atrial FibrillationAnjani Golive, Heidi T May, Tami L Bair, et al.
Journal of Cardiovascular Electrophysiology|August 14, 2015
Percent Time With a Supratherapeutic INR in Atrial Fibrillation Patients Also Using an Antiplatelet Agent Is Associated With Long-Term Risk of DementiaVictoria Jacobs, Scott C Woller, Scott M Stevens, et al.
American Heart Journal|June 5, 2017
Atrial fibrillation incrementally increases dementia risk across all CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>VASc strata in patients receiving long-term warfarinKevin G Graves, Heidi T May, Victoria Jacobs, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|August 9, 2011
Red cell distribution width, C-reactive protein, the complete blood count, and mortality in patients with coronary disease and a normal comparison populationJason M Lappé, Benjamin D Horne, Svati H Shah, et al.
Journal of Cardiovascular Electrophysiology|May 29, 2009
Warfarin is not needed in low-risk patients following atrial fibrillation ablation proceduresT Jared Bunch, Brian G Crandall, J Peter Weiss, et al.
Pacing and Clinical Electrophysiology : PACE|September 8, 2011
Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocksT Jared Bunch, Srijoy Mahapatra, David Murdock, et al.
Pageof 14